Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
About the Solid Tumors Drugs Market
The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
Technavio’s analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• F. Hoffmann-La Roche
• Novartis
• Celgene
• Johnson & Johnson
• Pfizer
• BMS
Other prominent vendors
• AbbVie
• AbGenomics
• ADC Therapeutics
• Advantagene
• Agensys
• Almac Group
• Ambrx
• Argos Therapeutics
• Array BioPharma
• Astellas Pharma
• AstraZeneca
• Bayer
• Biogen
• Biotech Pharmaceutical
• Boehringer Ingelheim
• Boston Biomedical
• Celldex Therapeutics
• Chugai Pharmaceutical
• Cold Genesys
• CTI BioPharma
• Daiichi Sankyo
• DNAtrix
• Ds-Pharma
• Eleison Pharmaceuticals
• Eli Lilly
• Endo Pharmaceuticals
• Formation Biologics
• Fortress Biotech
• Genmab
• GSK
• Immatics Biotechnologies
• Immunogen
• Immunomedics
• Intas Pharmaceuticals
• Kairos Therapeutics
• Kyowa Hakko Kirin
• MedImmune
• Merck
• Mersana Therapeutics
• Morphotek
• Neovii Biotech
• NewLink Genetics
• Northwest Biotherapeutics
• Novartis
• OncoMed Pharmaceuticals
• Oxford Biotherapeutics
• Peregrine Pharmaceuticals
• Polaris Pharmaceuticals
• Sanofi
• Seattle Genetics
• Spectrum Pharmaceuticals
• Stemcentrx
• Synthon Biopharmaceuticals
• TG Therapeutics
• XBiotech
Market driver
• Exposure to risk factors
• For a full, detailed list, view our report
Market challenge
• Patent expiration of top-selling drugs
• For a full, detailed list, view our report
Market trend
• Emergence of targeted and combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
Technavio’s analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• F. Hoffmann-La Roche
• Novartis
• Celgene
• Johnson & Johnson
• Pfizer
• BMS
Other prominent vendors
• AbbVie
• AbGenomics
• ADC Therapeutics
• Advantagene
• Agensys
• Almac Group
• Ambrx
• Argos Therapeutics
• Array BioPharma
• Astellas Pharma
• AstraZeneca
• Bayer
• Biogen
• Biotech Pharmaceutical
• Boehringer Ingelheim
• Boston Biomedical
• Celldex Therapeutics
• Chugai Pharmaceutical
• Cold Genesys
• CTI BioPharma
• Daiichi Sankyo
• DNAtrix
• Ds-Pharma
• Eleison Pharmaceuticals
• Eli Lilly
• Endo Pharmaceuticals
• Formation Biologics
• Fortress Biotech
• Genmab
• GSK
• Immatics Biotechnologies
• Immunogen
• Immunomedics
• Intas Pharmaceuticals
• Kairos Therapeutics
• Kyowa Hakko Kirin
• MedImmune
• Merck
• Mersana Therapeutics
• Morphotek
• Neovii Biotech
• NewLink Genetics
• Northwest Biotherapeutics
• Novartis
• OncoMed Pharmaceuticals
• Oxford Biotherapeutics
• Peregrine Pharmaceuticals
• Polaris Pharmaceuticals
• Sanofi
• Seattle Genetics
• Spectrum Pharmaceuticals
• Stemcentrx
• Synthon Biopharmaceuticals
• TG Therapeutics
• XBiotech
Market driver
• Exposure to risk factors
• For a full, detailed list, view our report
Market challenge
• Patent expiration of top-selling drugs
• For a full, detailed list, view our report
Market trend
• Emergence of targeted and combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
